Covalence Research Ltd, Rivers Lodge, West Common, Harpenden, AL5 2JD, UK.
Department of Renal Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Adv Ther. 2022 Oct;39(10):4678-4691. doi: 10.1007/s12325-022-02242-x. Epub 2022 Aug 10.
Intravenous (IV) iron is the preferred treatment for patients with iron deficiency anemia (IDA) who require rapid replenishment of iron stores or in whom oral iron is not tolerated or effective. Data from two large-scale randomized controlled trials (RCTs) have recently been published reporting the incidence of adjudicated cardiovascular events after ferric derisomaltose (FDI) and iron sucrose (IS). The objective was to calculate the relative incidence of cardiovascular events with FDI and IS, and to conduct an indirect comparison with ferric carboxymaltose (FCM) based on previously published studies of cardiovascular risk.
RCTs reporting the incidence of blindly adjudicated cardiovascular events in IDA patients treated with IV iron were identified by systematic literature review (SLR). Pairwise random effects meta-analyses of FDI versus IS, and FCM versus IS were conducted for the pre-specified adjudicated composite cardiovascular endpoint of: death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization, congestive heart failure, arrhythmia, and protocol-defined hypertensive and hypotensive events. Analyses were also conducted for the composite endpoint excluding blood pressure events. Meta-analysis results were combined in an adjusted indirect comparison to provide an indirect estimate of cardiovascular risk with FDI versus FCM.
The SLR retrieved 694 unique articles, of which four were RCTs reporting the incidence of the composite cardiovascular endpoint; two studies comparing FCM (N = 1529) with IS (N = 1505), and two studies comparing FDI (N = 2008) with IS (N = 1000). The odds ratios of the composite CV endpoint were 0.59 (95% confidence interval: 0.39-0.90) for FDI versus IS, 1.12 (95% CI 0.90-1.40) for FCM versus IS, and the indirect OR for FDI versus FCM was 0.53 (95% CI 0.33-0.85).
Pooling data from four large-scale RCTs suggested that FDI was associated with significantly lower incidence of cardiovascular adverse events compared to both FCM and IS.
静脉内(IV)铁是治疗缺铁性贫血(IDA)患者的首选方法,这些患者需要快速补充铁储存,或者口服铁不耐受或无效。最近发表了两项大型随机对照试验(RCT)的数据,报告了铁酸去铁胺(FDI)和蔗糖铁(IS)治疗后心血管不良事件的发生率。目的是计算 FDI 和 IS 的心血管事件相对发生率,并根据以前发表的心血管风险研究进行间接比较。
通过系统文献回顾(SLR)确定了报告 IV 铁治疗 IDA 患者盲法裁定心血管不良事件发生率的 RCT。对 FDI 与 IS 以及 FCM 与 IS 进行了预先指定的裁定复合心血管终点的成对随机效应荟萃分析:任何原因导致的死亡、非致命性心肌梗死、非致命性中风、需要住院治疗的不稳定型心绞痛、充血性心力衰竭、心律失常以及方案定义的高血压和低血压事件。还对不包括血压事件的复合终点进行了分析。荟萃分析结果在调整后的间接比较中合并,以提供 FDI 与 FCM 相比心血管风险的间接估计。
SLR 检索到 694 篇独特的文章,其中 4 篇为 RCT,报告了复合心血管终点的发生率;两项研究比较了 FCM(N=1529)与 IS(N=1505),两项研究比较了 FDI(N=2008)与 IS(N=1000)。FDI 与 IS 相比,复合 CV 终点的优势比(OR)为 0.59(95%置信区间:0.39-0.90),FCM 与 IS 相比为 1.12(95%CI 0.90-1.40),FDI 与 FCM 的间接 OR 为 0.53(95%CI 0.33-0.85)。
四项大型 RCT 的汇总数据表明,与 FCM 和 IS 相比,FDI 与心血管不良事件发生率显著降低相关。